NEW YORK (GenomeWeb) — Cepheid reported after the close of the market Thursday a 21 percent increase in second quarter revenues as it placed a record number of GeneXpert diagnostic systems during the period.

For the three months ended June 30, Cepheid logged revenues of $116.5 million compared to $96.0 million in Q2 2014, narrowly beating the average Wall Street estimate of $115.6 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.